Skyline Therapeutics (US) Inc.
1 clinical trials · Sponsor
◉ Watch Skyline Therapeutics (US) Inc.
| Record | Firm | Date |
|---|---|---|
| Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD) (NCT05986864) | Skyline Therapeutics (US) Inc. | 2024-02-23 |
Track Skyline Therapeutics (US) Inc. automatically
Every clearance here is in the API, with alerts when new ones post.